9- (3- (2- nitro- 1- imidazolyl)propylamino)- 1,2,3,4- tetrahydroacridine

01/01/1996 - "Toxicity studies in balb/c mice (without tumors) showed that THNLA-1 is well tolerated up to at least 70 mg/kg for more than 40 days while no toxicity was observed with the combined drugs used in our experimental protocol. "

01/01/1999 - "Finally, potential lethal damage repair was totally suppressed only in the hypoxia-pretreated cells with THNLA-1. "
01/01/1999 - "Significantly increased apoptosis was observed in the hypoxia-pretreated cells with THNLA-1, 12 and 24 h posttreatment. "
01/01/1996 - "The supra-additive effect is dependent on the hypoxia-pretreatment time with THNLA-1, on THNLA-1 concentration and on the concentration of the chemotherapeutic drug. "
01/01/1999 - "Comet and alkaline elution assay analysis showed increased DNA cross-links in the hypoxia-pretreated cells with THNLA-1 compared to the L-PAM-alone-treated cells. "
01/01/1994 - "THNLA-1 is a good hypoxia-selective cytotoxin with a differential toxicity of approximately equal to 11 in V79 cells, but it is approximately equal to 2 times less potent on a concentration basis than NLA-1 (the 2-nitroimidazole linked acridine analog). "